Business · 1 sources covering this

Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker

While the market's enthusiasm for one of Zealand's experimental drugs has cooled, investors are shifting focus to amylin-based medicines as a growth driver

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·2h ago
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
While the market's enthusiasm for one of Zealand's experimental drugs has cooled, investors are shifting focus to amylin-based medicines as a growth driver
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/d795de9c3e7eb81e8a6b934d4ea3023ebf51cae7"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker"></iframe>

Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker

How 1 sources are covering this

Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker

More from Business

'He hid the a la carte menu': Who should pay on the first date?

UK borrowing in May surges by more than expected

UK political uncertainty grows as Andy Burnham clears path to challenge PM Starmer

Oil rebounds as postponed U.S.-Iran talks temper optimism over ceasefire progress

Reader

Trust & legal

Across the network